SEC Form SC 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

$BDRX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BDRX alert in real time by email
SC 13G 1 ea0209895-13gbrio_biodexa.htm SCHEDULE 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934*

 

BIODEXA PHARMACEUTICALS PLC
(Name of Issuer)
 
AMERICAN DEPOSITORY SHARES**
(Title of Class of Securities)
 
59564R708***
(CUSIP Number)
 
July 15, 2024
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

   Rule 13d-1(b)

   Rule 13d-1(c)

   Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

**Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

 

***The CUSIP number applies to the American Depositary Shares of the Issuer.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No.   59564R708

 

1.

Names of Reporting Persons

 

Brio Capital Master Fund Ltd.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)   ☐

(b)   ☐

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization

 

Cayman Islands

Number of Shares

Beneficially Owned

By Each Reporting

Person With:

5.

Sole Voting Power

 

1,427,861 American Depository Shares(1) (2)

6.

Shared Voting Power

 

0

7.

Sole Dispositive Power

 

1,427,861 American Depository Shares(1) (2)

8.

Shared Dispositive Power

 

0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,427,861 American Depository Shares(1) (2)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒

 

See footnote (2) below. (See Instructions)

11.

Percent of Class Represented by Amount in Row (9)

 

9.83%(3)

12.

Type of Reporting Person (See Instructions)

 

CO

 

(1)Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

 

(2)This amount excludes American Depository Shares issuable upon exercise of the Warrants since each of these Warrants is not exercisable when holder beneficially owns in excess of 4.99% of the outstanding shares.

 

(3)Percentage calculation is based on the number of ordinary shares outstanding as of July 23, 2024, as reported on the company’s website.

 

2

 

 

CUSIP No.   59564R708

 

1.

Names of Reporting Persons

 

Brio Capital Management LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)   ☐

(b)   ☐

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Delaware, United States

Number of Shares

Beneficially Owned

By Each Reporting

Person With:

5.

Sole Voting Power

 

1,427,861 American Depository Shares (4)(5)

6.

Shared Voting Power

 

0

7.

Sole Dispositive Power

 

1,427,861 American Depository Shares (4)(5)

8.

Shared Dispositive Power

 

0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,427,861 American Depository Shares (4)(5)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒

 

See footnote (5) below. (See Instructions) 

11.

Percent of Class Represented by Amount in Row (9)

 

9.83%(6)

12.

Type of Reporting Person (See Instructions)

 

CO

 

(4)Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

 

(5)This amount excludes American Depository Shares issuable upon exercise of the Warrants since each of these Warrants is not exercisable when holder beneficially owns in excess of 4.99% of the outstanding shares.

 

(6)Percentage calculation is based on the number of ordinary shares outstanding as of July 23, 2024, as reported on the company’s website.

 

3

 

 

Item 1(a). Name of Issuer
   
  Biodexa Pharmaceuticals PLC (the “Issuer”)
   
Item 1(b). Address of the Issuer’s Principal Executive Offices
   
 

1 Caspian Point, Caspian Way

Cardiff, CF10 4DQ, United Kingdom.

   
Item 2(a). Names of Persons Filing

 

This Schedule 13G is filed jointly by:

 

  Brio Capital Master Fund Ltd.
  Brio Capital Management LLC

 

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person.

 

Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

 

Item 2(b). Address of the Principal Business Office, or if none, Residence:
   
  c/o Brio Capital Management LLC, 100 Merrick Road, Suite 401 W. Rockville Center, NY 11570.
   
Item 2(c). Citizenship

 

 

Brio Capital Master Fund Ltd. – Cayman Islands

Brio Capital Management LLC – United States

 

Item 2(d). Title of Class of Securities
   
 

American Depository Shares. Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

   
Item 2(e). CUSIP Number
   
  59564R708
   
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

  

  ¨ (a)  Broker or Dealer registered under Section 15 of the Exchange Act.
     
  ¨ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
     
  ¨ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
     
  ¨ (d) Investment company registered under Section 8 of the Investment Company Act.

 

  ¨ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
     
  ¨ (f)  An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
     
  ¨ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
     
  ¨ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
     
  ¨

(i) A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

     
  ¨ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
     
    Not applicable

 

4

 

 

Item 4.

Ownership

 

The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference.

 

Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

 

Item 5. Ownership of Five Percent or Less of a Class
   
  Not Applicable
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person
   
  Not Applicable 
   
Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

   
  Not Applicable
   
Item 8. Identification and Classification of Members of the Group
   
  Not Applicable
   
Item 9. Notice of Dissolution of Group
   
  Not Applicable
   
Item 10. Certification
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

5

 

 

LIST OF EXHIBITS

 

Exhibit No.   Description
     
Exhibit 1   Joint Filing Agreement

   

 

6

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

DATE:   July 23, 2024

 

  Brio Capital Master Fund Ltd.,
  a Cayman Islands Exempted Company
     
  By: Brio Capital Management LLC, its Investment Manager
     
  By: /s/ Shaye Hirsch
    Name:   Shaye Hirsch
    Title: Managing Member
     
  Brio Capital Management LLC,
  a Delaware limited liability company
     
  By: /s/ Shaye Hirsch
    Name: Shaye Hirsch
    Title: Managing Member

 

Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations

(See 18 U.S.C. 1001)

  

7

 

Get the next $BDRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BDRX

DatePrice TargetRatingAnalyst
2/8/2024$8.00Buy
Ladenburg Thalmann
More analyst ratings

$BDRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
  • Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

    MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1February 18, 2025 9:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
  • Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

    February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025. The live, interactive online event will give existing shareh

    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BDRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BDRX
SEC Filings

See more

$BDRX
Leadership Updates

Live Leadership Updates

See more
  • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance
  • Biodexa Appoints Ann Merchant to the Board of Directors

    Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

    $ALVO
    $BDRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$BDRX
Financials

Live finance-specific insights

See more
  • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

    CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BDRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more